American International Group Inc. Purchases 279 Shares of Exact Sciences Co. (NASDAQ:EXAS)

American International Group Inc. boosted its position in Exact Sciences Co. (NASDAQ:EXAS) by 14.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,191 shares of the medical research company’s stock after purchasing an additional 279 shares during the quarter. American International Group Inc.’s holdings in Exact Sciences were worth $206,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in EXAS. Park Place Capital Corp raised its holdings in Exact Sciences by 189.2% in the first quarter. Park Place Capital Corp now owns 376 shares of the medical research company’s stock worth $25,000 after purchasing an additional 246 shares in the last quarter. True Wealth Design LLC bought a new position in Exact Sciences in the fourth quarter worth about $30,000. TCI Wealth Advisors Inc. raised its holdings in Exact Sciences by 15,466.7% in the first quarter. TCI Wealth Advisors Inc. now owns 467 shares of the medical research company’s stock worth $32,000 after purchasing an additional 464 shares in the last quarter. Ameritas Advisory Services LLC bought a new position in Exact Sciences in the first quarter worth about $32,000. Finally, Money Concepts Capital Corp bought a new position in Exact Sciences in the fourth quarter worth about $36,000. 89.13% of the stock is currently owned by institutional investors.

Insider Activity at Exact Sciences

In related news, insider Everett Cunningham sold 13,007 shares of Exact Sciences stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $66.49, for a total value of $864,835.43. Following the sale, the insider now owns 37,909 shares of the company’s stock, valued at approximately $2,520,569.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

EXAS has been the subject of several research analyst reports. Robert W. Baird increased their price objective on shares of Exact Sciences from $99.00 to $121.00 and gave the company an “outperform” rating in a research report on Wednesday, August 2nd. Bank of America increased their price objective on shares of Exact Sciences from $105.00 to $110.00 in a research report on Wednesday, August 2nd. The Goldman Sachs Group decreased their price objective on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. Benchmark lowered shares of Exact Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Finally, Piper Sandler decreased their price objective on shares of Exact Sciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, October 16th. Five investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.56.

Exact Sciences Price Performance

Shares of NASDAQ EXAS opened at $67.29 on Tuesday. The stock has a market capitalization of $12.17 billion, a price-to-earnings ratio of -42.32 and a beta of 1.46. Exact Sciences Co. has a 12 month low of $40.73 and a 12 month high of $100.77. The firm’s 50 day simple moving average is $66.20 and its 200-day simple moving average is $79.81. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.41 and a quick ratio of 2.13.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.